An open-label expanded access study of trifluridine/tipiracil for metastatic colorectal cancer.

被引：4
|
作者：
Mayer, Robert J.
Grothey, Axel
Hochster, Howard S.
Cohen, Steven J.
Vukovic, Vojislav M.
Makris, Lukas
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Daisuke Kotani
    Yasutoshi Kuboki
    Satoshi Horasawa
    Asumi Kaneko
    Yoshiaki Nakamura
    Akihito Kawazoe
    Hideaki Bando
    Hiroya Taniguchi
    Kohei Shitara
    Takashi Kojima
    Akihito Tsuji
    Takayuki Yoshino
    BMC Cancer, 19
  • [32] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
  • [33] Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    Masuishi, Toshiki
    Moriwaki, Toshikazu
    Fukuoka, Shota
    Takashima, Atsuo
    Kumekawa, Yosuke
    Kajiwara, Takeshi
    Yamazaki, Kentaro
    Esaki, Taito
    Makiyama, Akitaka
    Denda, Tadamichi
    Satake, Hironaga
    Suto, Takeshi
    Sugimoto, Naotoshi
    Katsumata, Kenji
    Ishikawa, Toshiaki
    Kashiwada, Tomomi
    Oki, Eiji
    Komatsu, Yoshito
    Yoshimura, Kenichi
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
    Tabernero, Josep
    Van Cutsem, Eric
    Ohtsu, Atsushi
    Amellal, Nadia
    Cadour, Stephanie
    Fougeray, Ronan
    Haffemayer, Benjamin
    Mayer, Robert J.
    ESMO OPEN, 2017, 2 (05)
  • [35] A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice
    Borelli, Beatrice
    Zucchelli, Gemma
    Rossini, Daniele
    Cremolini, Chiara
    Antoniotti, Carlotta
    Moretto, Roberto
    Marmorino, Federica
    Colombo, Camilla
    Vannini, Francesca
    Delliponti, Laura
    Spione, Mario
    Ongaro, Elena
    Masi, Gianluca
    Brunetti, Isa Maura
    Pfanner, Elisabetta
    Salvatore, Lisa
    Falcone, Alfredo
    COLORECTAL CANCER, 2018, 7 (01)
  • [36] Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil
    Puthiamadathil, Jeevan M.
    Weinberg, Benjamin A.
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 461 - 469
  • [37] Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
    Tasseau, Clara
    Gallois, Claire
    BULLETIN DU CANCER, 2024, 111 (12) : 1087 - 1088
  • [38] A budget impact model of third-line or later trifluridine/tipiracil treatment of metastatic colorectal cancer.
    Ferrufino, Cheryl
    Wiseman, Fred
    Wert, Tim D.
    Barghout, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
    Zaniboni, Alberto
    Barone, Carlo Antonio
    Banzi, Maria Chiara
    Bergamo, Francesca
    Blasi, Livio
    Bordonaro, Roberto
    Di Bartolomeo, Maria
    Di Costanzo, Francesco
    Frassineti, Giovanni Luca
    Garufi, Carlo
    Giuliani, Francesco
    Latiano, Tiziana Pia
    Martinelli, Erika
    Personeni, Nicola
    Racca, Patrizia
    Tamburini, Emiliano
    Tonini, Giuseppe
    Besse, Marie Georges
    Spione, Mario
    Falcone, Alfredo
    FUTURE ONCOLOGY, 2021, 17 (18) : 2315 - 2324
  • [40] Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Funato, Yuya
    Yamaguchi, Yasunobu
    Koyama, Takahiko
    Ozawa, Daisuke
    Tajiri, Masaru
    Muro, Kei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 700 - 706
12345